Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

NEW EPISODE
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
NEW EPISODE
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Long-Term Zanubrutinib Outcomes
EHA 2026: Long-Term Zanubrutinib Outcomes
Oncology and Hematology
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
- Alessandra Tedeschi, MD
NEW EPISODE
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
De Novo mHSPC: Recognizing the Patients Who Need More
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Oncology and Hematology
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD; Louise Lim, MD
- Nicolas Girard, MD
- Louise Lim, MD
- Jacob Sands, MD
- Stephanie McDonald, MSN, FNP-BC, AOCNP
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits

Medical News

Medical News
Mental Health Burden in Long-Term Survivors of Childhood and Young Adult Cancer
06/23/2026
Read more
$talquetamab and daratumumab in relapsed or refractory myeloma$ $talquetamab and daratumumab in relapsed or refractory myeloma$
Medical News
Talquetamab and Daratumumab in Relapsed or Refractory Myeloma
06/18/2026
Read more
Medical News
Olaparib Plus Radium-223 Improves rPFS in COMRADE
06/18/2026
Read more
Medical News
Text Messaging and FIT Completion in a Quality Improvement Trial
06/18/2026
Read more

CME/CE

NEW EPISODE
Case: Implementing ADT Intensification in mHSPC
Case: Implementing ADT Intensification in mHSPC
MinuteCE®
Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
MinuteCE®
Treatment Intensification in HSPC: From Risk Stratification to Precision Medicine
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 credit 6 episodes
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 credit 6 episodes
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits

Clinical Practice

Post-BCMA Treatment Selection in R/R Multiple Myeloma
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Project Oncology®
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD; Nisha Joseph, MD
- Steve Jackson, PharmD
- Nisha Joseph, MD
In-Person Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits

Programs

6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD; Lyudmila A. Bazhenova, MD
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
Assessing and Interpreting pCR in Perioperative NSCLC
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD; Alexander Spira, MD, PhD, FACP
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP